Looking for research-grade compounds?
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth factor. Selank begins as a fragment of an antibody. It is a synthetic, stabilized analog of tuftsin — a naturally occurring immune peptide — engineered in Russia to survive long enough in biological systems to be studied for effects on neurotransmission, stress-related behavior, and immune signaling. That dual heritage, immune and neurological, is what makes selank peptide research distinct, and it is also why researchers need to read the evidence carefully: the human data are real but small, largely Russian, and not replicated to Western regulatory standards.
This article is for laboratory research education only. It covers what Selank is, how it was designed, what mechanisms have been proposed in published studies, what the human and animal literature actually found, and what its regulatory status is — and is not — in the United States, Europe, and Russia.
Selank is a heptapeptide — a chain of seven amino acids — with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP. Its molecular formula is C33H57N11O9, its molecular weight is about 751.9 g/mol, and its CAS number is 129954-34-3. It is also known in the literature as TP-7 and, in its Russian marketed form, as Selanc.
The first four amino acids, Thr-Lys-Pro-Arg, are tuftsin itself. Tuftsin is cleaved from the Fc region of immunoglobulin G (IgG) and was first described for its role in stimulating phagocytic activity in immune cells. On its own, tuftsin is degraded very rapidly by peptidases, which limits its usefulness as an experimental tool.
Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with the V.V. Zakusov Research Institute of Pharmacology, addressed that limitation by appending a Pro-Gly-Pro tripeptide to the C-terminus. That extension — a motif also used in other Russian peptide designs to resist enzymatic breakdown — produced Selank: a molecule that retains tuftsin-like immunomodulatory activity in preclinical models while showing additional effects on central neurotransmitter systems that tuftsin alone does not explain.
For researchers sourcing material, identity matters here. Selank is not tuftsin, not N-acetyl Selank, and not N-acetyl Selank amidate — those modified forms have different structures and, critically, no dedicated human study record of their own. A certificate of analysis should confirm the exact TKPRPGP sequence by mass spectrometry, not just a trade name. Our guides to peptide HPLC purity testing and COA testing at Apex Bio explain how identity and purity are documented separately.
In the Apex catalog, the compound is supplied as a Selank research peptide strictly for laboratory research use.
Selank was developed during the 1990s as part of a broader Russian program on short regulatory peptides — the same program that produced Semax, a heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH). The two compounds are often discussed together because both are seven amino acids long, both were designed for stability, and both were registered as medicines in Russia. They are not interchangeable: they come from different parent molecules, are studied for different primary questions, and have different proposed mechanisms.
Key milestones in the published record include:
That timeline is useful for calibration. Selank peptide research is not new, and it is not a single-study story. It is, however, concentrated: most work comes from the developing institutions and affiliated groups, much of it published in Russian-language journals, and independent replication outside that network remains limited.
No single receptor explains Selank in the way a single receptor explains, for example, a GLP-1 agonist. The literature proposes several converging mechanisms. Each should be read as a laboratory finding, not as a proven human effect.
The most developed mechanistic hypothesis is that Selank modulates the GABAergic system allosterically — influencing how GABA-A receptors respond to GABA rather than acting as a direct benzodiazepine-site agonist. Volkova et al. (Frontiers in Pharmacology, 2016, PMID 26924987) measured mRNA levels for 84 neurotransmission-related genes in rat frontal cortex 1 and 3 hours after administration of Selank or GABA. They found significant changes in 45 genes at 1 hour and 22 genes at 3 hours, with a positive correlation between the Selank and GABA expression patterns, and concluded that one possible molecular mechanism is allosteric modulation of the GABAergic system. A follow-up study in IMR-32 neuroblastoma cells (Filatova et al., 2017) found no direct effect of Selank alone on the same gene set in that cell model, which the authors interpreted as consistent with an interaction effect on GABA-receptor function rather than direct transcriptional action in isolated cells. Researchers should note both results: the in vivo signal and the in vitro qualification.
Enkephalins are endogenous opioid peptides involved in stress adaptation and emotional regulation, and they are rapidly broken down by enkephalinase enzymes. Zozulya et al. (2001) reported that Selank inhibited those degrading enzymes, which would be expected in a laboratory system to prolong enkephalin signaling. This mechanism is frequently cited for Selank’s anxiolytic-like profile in animal work, distinct from both benzodiazepines and monoamine reuptake inhibitors.
Animal studies, including work by Semenova and colleagues (2008) on integrative brain activity and biogenic amine levels, report that Selank influences serotonin metabolism and catecholamine measures in stress-responsive brain regions. The pattern described in the literature is normalization under stress conditions rather than a simple global increase or decrease. Human mechanistic data for monoamine effects are indirect and should not be overstated.
Inozemtseva et al. (Doklady Biological Sciences, 2008) reported that intranasal Selank regulated BDNF expression in the rat hippocampus in vivo. Kozlovskii and colleagues (2019) later reported that Selank protected against ethanol-induced memory impairment in rats in association with regulation of BDNF content in hippocampus and prefrontal cortex. BDNF is a neurotrophin involved in synaptic plasticity and learning-related processes, which is why this line of work attracts attention from cognition researchers. It remains animal work: no human study has demonstrated a BDNF-mediated cognitive effect for Selank.
True to its origin, Selank has been studied for effects on cytokine balance. Uchakina et al. (2008) reported immunomodulatory effects in patients with anxiety-asthenic disorders, including changes related to Th1/Th2 balance and interleukin-6. Kolomin et al. (2014) examined the time course of inflammation-related gene expression under Selank in an experimental model. For neuroimmunology researchers, this immune arm — not the anxiety literature — may be the most distinctive reason to include Selank in a study design, for example alongside the immune-focused work covered in our broader peptide research library.
The human evidence for Selank consists of small Russian clinical studies, mostly open-label or active-comparator designs without placebo arms. That design limitation shapes every conclusion below.
| Study | Design | What was reported | Key limitation |
|---|---|---|---|
| Zozulia et al., 2008 (PMID 18454096) | 62 patients with generalized anxiety disorder and neurasthenia; Selank (n=30) vs medazepam (n=32) | Similar anxiolytic scores on standard anxiety scales for both groups; authors also described antiasthenic effects for Selank | No placebo group; open comparison; Russian-language journal |
| Uchakina et al., 2008 | Patients with anxiety-asthenic disorders | Immunomodulatory changes alongside clinical observation | Small sample; mechanistic endpoints, not a powered efficacy trial |
| Medvedev et al., 2014–2015 | Comparisons and add-on work with phenazepam (n=60 and n=70 in reported cohorts) | Authors reported comparable anxiety improvement and, in the add-on cohort, fewer phenazepam-associated effects when Selank was combined | Combination data do not test Selank alone; not independently replicated |
Three points matter for a fair reading. First, an active-comparator result — “similar to medazepam in this cohort” — does not establish efficacy versus placebo, and it does not establish equivalence in the regulatory sense. Second, claims sometimes repeated online that Selank has been proven to cause no sedation, dependence, or withdrawal go beyond the designs used: those outcomes were not tested in long-term, controlled dependence studies. Third, there are no large Western randomized controlled trials of Selank, and no FDA or EMA review of its efficacy. A researcher citing the human literature should cite it as preliminary, single-country, developer-affiliated evidence — interesting, and hypothesis-generating, but not settled.
| Feature | Selank | Semax | Tuftsin |
|---|---|---|---|
| Parent molecule | Tuftsin + Pro-Gly-Pro extension | ACTH(4-7) fragment + Pro-Gly-Pro extension | IgG heavy chain fragment itself |
| Sequence / size | TKPRPGP, 7 amino acids | MEHFPGP, 7 amino acids | TKPR, 4 amino acids |
| Primary research focus | GABAergic modulation, enkephalins, immune signaling | Neurotrophic factors, cognition models | Phagocytosis and immune activation |
| Stability | Designed for improved peptidase resistance | Designed for improved peptidase resistance | Rapidly degraded |
| FDA approval | No | No | No |
| Registered in Russia | Yes, 2009, anxiety/neurasthenia indications there | Yes, different neurological indications there | No |
Researchers building a panel sometimes include Selank and Semax together because their mechanisms are described differently — GABA/enkephalin-focused versus neurotrophin-focused. No clinical trial has evaluated the combination, and interaction data are limited to animal work such as the diazepam study noted above. Treating the pair as an established combination would misrepresent the literature.
Russia: Selank is a registered medicine, supplied as 0.15% nasal drops, approved in 2009 for generalized anxiety disorder and neurasthenia in that system. That approval reflects Russian regulatory review of the Russian study program.
United States: Selank is not FDA-approved for any indication. It has not completed FDA review, and it is not an approved drug product in the US. In FDA compounding records summarized in recent regulatory reviews, selank acetate was nominated for the 503A bulks list and the nomination was withdrawn; it is not on the 503A Bulks List, so there is no current 503A compounding pathway based on that nomination. In the US, material sold as Selank is therefore supplied strictly as a research chemical for laboratory use — not for human consumption, diagnosis, or treatment.
European Union: Selank is not centrally authorized by the European Medicines Agency (EMA) and is not an approved medicine in the EU.
Sport: Researchers working with athletic-testing models should check the current WADA Prohibited List directly rather than relying on summaries, as classifications for peptide classes are updated annually.
A useful contrast from our recent coverage is the telomere-focused tetrapeptide in Epithalon peptide research: like Selank, it has a long Russian research history, PCAC compounding debate in the US, and no FDA approval — a reminder that a long publication history and US regulatory approval are different things.
For in vitro and preclinical research design, the literature suggests several practical points:
No. Selank is not FDA-approved for any indication in the United States and is not EMA-authorized in Europe. It was registered in Russia in 2009. In the US it is supplied strictly for laboratory research use.
No. Selank contains the tuftsin sequence (Thr-Lys-Pro-Arg) plus a Pro-Gly-Pro extension added to improve stability. That structural change is associated in the literature with additional central effects not attributed to tuftsin alone, and the two should not be cited interchangeably.
No single direct receptor target has been established in the way, for example, a GLP-1 receptor agonist’s target has. The leading published hypotheses are allosteric modulation of the GABAergic system (Volkova et al., 2016), inhibition of enkephalin-degrading enzymes (Zozulya et al., 2001), and effects on monoamine metabolism and BDNF expression in animal models.
Preliminary. The largest study enrolled 62 patients, used an active comparator (medazepam) rather than placebo, and was published in a Russian-language journal in 2008. There are no large, independently replicated, placebo-controlled trials and no Western regulatory review of efficacy.
In rats, intranasal Selank regulated BDNF expression in the hippocampus in vivo (Inozemtseva et al., 2008), and later rat work linked Selank to BDNF content in hippocampus and prefrontal cortex in a memory-impairment model. No human BDNF effect has been demonstrated.
Both are Russian-designed, Pro-Gly-Pro-stabilized heptapeptides registered as medicines in Russia, but they derive from different parent molecules — tuftsin for Selank, an ACTH fragment for Semax — and are studied for different primary mechanisms. The comparison is structural and historical, not evidence that they are interchangeable or that a combination has been tested in humans.
Selank is one of the more fully described short peptides in the Russian research literature: a rationally stabilized tuftsin analog with a defined sequence, a proposed GABAergic and enkephalin-related mechanism supported by gene-expression and enzyme work, a BDNF signal in animal models, and an immunomodulatory heritage that sets it apart from purely neurological compounds. It is also a clear example of the gap between a national approval based on a domestic study program and the standard of evidence required by the FDA or EMA — a gap researchers should state plainly in any paper, grant, or protocol that cites this literature.
Handled that way — exact identity, verified purity, time-aware endpoints, and honest limits on the human data — selank peptide research remains a legitimate and interesting area of laboratory inquiry.
Related in the Apex shop: Selank research peptide — supplied strictly for laboratory research use.
Disclaimer: This article is for educational and laboratory research purposes only. All products discussed are supplied strictly as research chemicals for in vitro and laboratory research use only, not for human or veterinary use, consumption, diagnostic, or therapeutic purposes. Nothing in this article is medical advice or a claim of safety or efficacy for any human use.
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
Tirzepatide peptide research is built around a question the incretin field argued about for two decades: what happens if one
